-
Something wrong with this record ?
Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs
R. Vrzal,
Language English Country England, Great Britain
Document type Journal Article
PubMed
26821071
DOI
10.1111/fcp.12183
Knihovny.cz E-resources
- MeSH
- Anthocyanins administration & dosage metabolism MeSH
- Administration, Oral MeSH
- Fluoresceins administration & dosage metabolism MeSH
- Food-Drug Interactions * physiology MeSH
- Humans MeSH
- ATP Binding Cassette Transporter, Subfamily B, Member 1 antagonists & inhibitors metabolism MeSH
- Dietary Supplements * MeSH
- Swine MeSH
- Verapamil administration & dosage metabolism MeSH
- Dose-Response Relationship, Drug MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
P-glycoprotein (P-gp) inhibition represents a promising therapeutic strategy for oncologic patients. The inhibition by naturally occurring anthocyans would bring certain benefits. Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy. However, due to the food supplementation, significant concentration can raise up in the intestine, where P-gp is abundantly expressed. As many drugs are orally taken, simultaneous administration might affect the concentration of these drugs in the blood. Here, we found that anthocyanidins (aglycons) but not anthocyanins (glycosides) can significantly inhibit P-gp up to 60% of positive control, verapamil. This inhibitory activity was observed for 500 μm concentrations of malvidin and pelargonidin. We conclude that these compounds may be the source of food-drug interactions either for orally taken drugs or for intravenously administered drugs eliminated via biliary excretion which are the substrates of P-gp.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024177
- 003
- CZ-PrNML
- 005
- 20170906132631.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/fcp.12183 $2 doi
- 035 __
- $a (PubMed)26821071
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vrzal, Radim $u Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71, Olomouc, Czech Republic.
- 245 10
- $a Anthocyanidins but not anthocyanins inhibit P-glycoprotein-mediated calcein extrusion - possible implication for orally administered drugs / $c R. Vrzal,
- 520 9_
- $a P-glycoprotein (P-gp) inhibition represents a promising therapeutic strategy for oncologic patients. The inhibition by naturally occurring anthocyans would bring certain benefits. Unfortunately, due to the low bioavailability and consequently low blood level, they cannot be used for cancer therapy. However, due to the food supplementation, significant concentration can raise up in the intestine, where P-gp is abundantly expressed. As many drugs are orally taken, simultaneous administration might affect the concentration of these drugs in the blood. Here, we found that anthocyanidins (aglycons) but not anthocyanins (glycosides) can significantly inhibit P-gp up to 60% of positive control, verapamil. This inhibitory activity was observed for 500 μm concentrations of malvidin and pelargonidin. We conclude that these compounds may be the source of food-drug interactions either for orally taken drugs or for intravenously administered drugs eliminated via biliary excretion which are the substrates of P-gp.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a anthokyaniny $x aplikace a dávkování $x metabolismus $7 D000872
- 650 12
- $a potravní doplňky $7 D019587
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a fluoresceiny $x aplikace a dávkování $x metabolismus $7 D005452
- 650 12
- $a interakce mezi potravou a léky $x fyziologie $7 D018565
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a P-glykoprotein $x antagonisté a inhibitory $x metabolismus $7 D020168
- 650 _2
- $a prasata $7 D013552
- 650 _2
- $a verapamil $x aplikace a dávkování $x metabolismus $7 D014700
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00001866 $t Fundamental & clinical pharmacology $x 1472-8206 $g Roč. 30, č. 3 (2016), s. 248-52
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26821071 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20170906133229 $b ABA008
- 999 __
- $a ok $b bmc $g 1239858 $s 985090
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 30 $c 3 $d 248-52 $e 20160215 $i 1472-8206 $m Fundamental & clinical pharmacology $n Fundam Clin Pharmacol $x MED00001866
- LZP __
- $a Pubmed-20170720